| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angioplasty, Balloon, Coronary | 14 | 2012 | 178 | 1.280 |
Why?
|
| Coronary Artery Disease | 8 | 2022 | 696 | 1.280 |
Why?
|
| Coronary Circulation | 19 | 2013 | 136 | 1.260 |
Why?
|
| Cardiac Catheterization | 16 | 2020 | 419 | 1.230 |
Why?
|
| Coronary Vessels | 13 | 2022 | 313 | 1.200 |
Why?
|
| Myocardial Infarction | 20 | 2019 | 807 | 1.010 |
Why?
|
| Drug-Eluting Stents | 3 | 2020 | 51 | 0.940 |
Why?
|
| Coronary Angiography | 25 | 2022 | 866 | 0.860 |
Why?
|
| Percutaneous Coronary Intervention | 3 | 2020 | 137 | 0.850 |
Why?
|
| Coronary Stenosis | 9 | 2014 | 246 | 0.750 |
Why?
|
| Myocardial Reperfusion | 3 | 2013 | 32 | 0.730 |
Why?
|
| Coronary Artery Bypass | 4 | 2020 | 218 | 0.730 |
Why?
|
| Plaque, Atherosclerotic | 4 | 2022 | 125 | 0.610 |
Why?
|
| Arteriosclerosis | 17 | 2001 | 137 | 0.560 |
Why?
|
| Coronary Disease | 14 | 2005 | 358 | 0.560 |
Why?
|
| Blood Flow Velocity | 6 | 2013 | 172 | 0.550 |
Why?
|
| Thrombosis | 2 | 2016 | 218 | 0.530 |
Why?
|
| Angioplasty, Balloon | 17 | 2001 | 110 | 0.520 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2014 | 164 | 0.510 |
Why?
|
| Aortic Valve | 2 | 2014 | 249 | 0.510 |
Why?
|
| Saphenous Vein | 1 | 2014 | 61 | 0.480 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2014 | 36 | 0.480 |
Why?
|
| Aneurysm | 1 | 2014 | 53 | 0.480 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 62 | 0.470 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 694 | 0.460 |
Why?
|
| Thrombectomy | 1 | 2016 | 238 | 0.460 |
Why?
|
| Heart Valve Diseases | 1 | 2014 | 123 | 0.430 |
Why?
|
| Lipids | 2 | 2022 | 298 | 0.430 |
Why?
|
| Mitral Valve | 1 | 2014 | 166 | 0.430 |
Why?
|
| Stents | 9 | 2006 | 657 | 0.430 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2020 | 31 | 0.420 |
Why?
|
| Myocardial Ischemia | 6 | 2013 | 172 | 0.400 |
Why?
|
| Atherectomy, Coronary | 2 | 2004 | 5 | 0.400 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 5 | 2008 | 137 | 0.390 |
Why?
|
| Middle Aged | 54 | 2021 | 21147 | 0.380 |
Why?
|
| Femoral Artery | 15 | 2001 | 139 | 0.370 |
Why?
|
| Echocardiography | 11 | 2021 | 515 | 0.370 |
Why?
|
| Heart Diseases | 3 | 2021 | 276 | 0.370 |
Why?
|
| Humans | 76 | 2022 | 68618 | 0.360 |
Why?
|
| Male | 73 | 2021 | 37321 | 0.350 |
Why?
|
| Heparin | 6 | 2017 | 205 | 0.350 |
Why?
|
| Blood Pressure | 7 | 2013 | 1451 | 0.340 |
Why?
|
| Aged | 31 | 2020 | 14862 | 0.330 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2020 | 102 | 0.330 |
Why?
|
| Anticoagulants | 5 | 2017 | 356 | 0.330 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2007 | 137 | 0.320 |
Why?
|
| Heart Failure | 9 | 2019 | 1180 | 0.310 |
Why?
|
| Female | 61 | 2021 | 38074 | 0.300 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 232 | 0.290 |
Why?
|
| Coronary Restenosis | 2 | 2004 | 42 | 0.280 |
Why?
|
| Hirudins | 8 | 2012 | 32 | 0.270 |
Why?
|
| Hemorrhage | 6 | 2017 | 328 | 0.270 |
Why?
|
| Thrombin | 5 | 1999 | 117 | 0.260 |
Why?
|
| Ultrasonography, Interventional | 3 | 2022 | 119 | 0.260 |
Why?
|
| Treatment Outcome | 15 | 2020 | 7029 | 0.250 |
Why?
|
| Myocardial Revascularization | 5 | 2007 | 56 | 0.250 |
Why?
|
| Prospective Studies | 14 | 2022 | 3705 | 0.240 |
Why?
|
| Coronary Thrombosis | 2 | 2016 | 45 | 0.230 |
Why?
|
| Stroke Volume | 12 | 2019 | 586 | 0.230 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 3259 | 0.210 |
Why?
|
| Diabetic Angiopathies | 1 | 2004 | 203 | 0.210 |
Why?
|
| Diabetic Nephropathies | 1 | 2004 | 161 | 0.210 |
Why?
|
| Myocardial Contraction | 9 | 2004 | 383 | 0.210 |
Why?
|
| Angina Pectoris | 3 | 2013 | 61 | 0.210 |
Why?
|
| Risk Factors | 10 | 2013 | 5731 | 0.200 |
Why?
|
| Adenosine | 4 | 2013 | 165 | 0.200 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 12 | 0.190 |
Why?
|
| Kidney Failure, Chronic | 1 | 2004 | 365 | 0.190 |
Why?
|
| Inservice Training | 1 | 2021 | 68 | 0.190 |
Why?
|
| Predictive Value of Tests | 8 | 2021 | 1465 | 0.180 |
Why?
|
| Education, Medical, Continuing | 1 | 2021 | 136 | 0.180 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2012 | 373 | 0.170 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2019 | 10 | 0.170 |
Why?
|
| Surgical Procedures, Operative | 1 | 2000 | 124 | 0.170 |
Why?
|
| Blood Vessel Prosthesis Implantation | 4 | 2006 | 186 | 0.160 |
Why?
|
| Pulmonary Artery | 1 | 2020 | 323 | 0.150 |
Why?
|
| Time Factors | 13 | 2017 | 4655 | 0.150 |
Why?
|
| Cardiovascular Diseases | 2 | 2009 | 940 | 0.150 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 195 | 0.150 |
Why?
|
| Contrast Media | 5 | 2003 | 595 | 0.150 |
Why?
|
| Recurrence | 17 | 2011 | 948 | 0.150 |
Why?
|
| Ventricular Dysfunction, Left | 4 | 2007 | 277 | 0.150 |
Why?
|
| Severity of Illness Index | 9 | 2019 | 1851 | 0.140 |
Why?
|
| Myocardium | 7 | 2003 | 1204 | 0.140 |
Why?
|
| Radiography | 6 | 2014 | 572 | 0.140 |
Why?
|
| Vasodilator Agents | 3 | 2005 | 138 | 0.140 |
Why?
|
| Postoperative Complications | 3 | 2014 | 1615 | 0.130 |
Why?
|
| Statistics as Topic | 3 | 2013 | 219 | 0.130 |
Why?
|
| Rabbits | 16 | 2001 | 509 | 0.130 |
Why?
|
| Technetium Tc 99m Sestamibi | 5 | 2007 | 24 | 0.120 |
Why?
|
| Survival Analysis | 3 | 2006 | 714 | 0.120 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2012 | 80 | 0.120 |
Why?
|
| Hemodynamics | 7 | 2019 | 705 | 0.120 |
Why?
|
| Coronary Aneurysm | 1 | 2014 | 19 | 0.120 |
Why?
|
| Radiopharmaceuticals | 5 | 2007 | 114 | 0.120 |
Why?
|
| Mass Screening | 1 | 2000 | 843 | 0.120 |
Why?
|
| Aortic Aneurysm | 1 | 2014 | 77 | 0.120 |
Why?
|
| Platelet Activation | 1 | 1993 | 24 | 0.120 |
Why?
|
| Dyspnea | 1 | 2014 | 87 | 0.110 |
Why?
|
| Aged, 80 and over | 4 | 2013 | 4848 | 0.110 |
Why?
|
| Fatigue | 1 | 2014 | 132 | 0.110 |
Why?
|
| Heart | 6 | 1997 | 850 | 0.110 |
Why?
|
| Reoperation | 1 | 2014 | 467 | 0.110 |
Why?
|
| Electrocardiography | 3 | 2004 | 601 | 0.110 |
Why?
|
| Ablation Techniques | 1 | 2013 | 33 | 0.110 |
Why?
|
| Prosthesis Design | 1 | 2014 | 301 | 0.110 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 333 | 0.110 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 23 | 0.100 |
Why?
|
| Heart Valve Prosthesis | 1 | 2014 | 222 | 0.100 |
Why?
|
| Blood Coagulation Disorders | 1 | 2012 | 45 | 0.100 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2013 | 116 | 0.100 |
Why?
|
| Embolism, Cholesterol | 1 | 2011 | 3 | 0.100 |
Why?
|
| Vascular Resistance | 3 | 1993 | 179 | 0.100 |
Why?
|
| Age Factors | 3 | 2013 | 1864 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 60 | 0.100 |
Why?
|
| Angioplasty | 2 | 2011 | 118 | 0.100 |
Why?
|
| Aortic Valve Stenosis | 2 | 2013 | 177 | 0.100 |
Why?
|
| Radial Artery | 1 | 2012 | 43 | 0.100 |
Why?
|
| Recovery of Function | 4 | 2013 | 506 | 0.100 |
Why?
|
| Prognosis | 6 | 2019 | 2093 | 0.090 |
Why?
|
| Tyrosine | 2 | 2002 | 196 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2006 | 1046 | 0.090 |
Why?
|
| Prevalence | 2 | 2006 | 1619 | 0.090 |
Why?
|
| Cardiotonic Agents | 3 | 1996 | 71 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2006 | 140 | 0.090 |
Why?
|
| Carotid Artery Injuries | 2 | 2001 | 26 | 0.090 |
Why?
|
| Sensitivity and Specificity | 7 | 2019 | 1753 | 0.090 |
Why?
|
| Histocompatibility | 1 | 1989 | 17 | 0.090 |
Why?
|
| Patient Safety | 1 | 2012 | 202 | 0.090 |
Why?
|
| Catheterization | 2 | 1997 | 209 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 1076 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2013 | 867 | 0.080 |
Why?
|
| Virginia | 2 | 2006 | 45 | 0.080 |
Why?
|
| HLA Antigens | 1 | 1989 | 82 | 0.080 |
Why?
|
| Peptide Fragments | 3 | 2012 | 483 | 0.080 |
Why?
|
| Collateral Circulation | 4 | 1996 | 34 | 0.080 |
Why?
|
| Adult | 16 | 2021 | 21403 | 0.080 |
Why?
|
| Heart Rate | 5 | 1996 | 568 | 0.080 |
Why?
|
| Captopril | 3 | 1989 | 22 | 0.080 |
Why?
|
| Ultrasonography | 3 | 2011 | 453 | 0.080 |
Why?
|
| Bed Rest | 2 | 2000 | 17 | 0.080 |
Why?
|
| Ticlopidine | 1 | 2009 | 118 | 0.080 |
Why?
|
| Albumins | 2 | 2000 | 72 | 0.080 |
Why?
|
| Dogs | 9 | 2007 | 490 | 0.080 |
Why?
|
| Cineradiography | 1 | 1988 | 12 | 0.080 |
Why?
|
| Ventricular Function, Left | 3 | 2005 | 481 | 0.080 |
Why?
|
| Antithrombins | 2 | 1999 | 32 | 0.080 |
Why?
|
| Animals | 28 | 2007 | 20881 | 0.080 |
Why?
|
| Retrospective Studies | 7 | 2017 | 7277 | 0.070 |
Why?
|
| Hospitalization | 1 | 2013 | 978 | 0.070 |
Why?
|
| Catecholamines | 1 | 2007 | 73 | 0.070 |
Why?
|
| Partial Thromboplastin Time | 5 | 2017 | 57 | 0.070 |
Why?
|
| Vasoconstriction | 1 | 2007 | 81 | 0.070 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2001 | 134 | 0.070 |
Why?
|
| Dobutamine | 2 | 2004 | 25 | 0.070 |
Why?
|
| Ethanol | 1 | 2013 | 893 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 1989 | 328 | 0.070 |
Why?
|
| Carbon Dioxide | 1 | 1986 | 78 | 0.070 |
Why?
|
| Fibrin Tissue Adhesive | 2 | 1997 | 17 | 0.070 |
Why?
|
| Hemostasis, Surgical | 2 | 1997 | 18 | 0.070 |
Why?
|
| Graft Rejection | 1 | 1989 | 458 | 0.070 |
Why?
|
| Thallium Radioisotopes | 3 | 1997 | 13 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2009 | 335 | 0.060 |
Why?
|
| Tunica Intima | 4 | 2001 | 59 | 0.060 |
Why?
|
| Comorbidity | 2 | 2013 | 1426 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2077 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2006 | 1553 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 237 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2002 | 48 | 0.060 |
Why?
|
| Angioplasty, Laser | 2 | 1995 | 4 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2007 | 689 | 0.060 |
Why?
|
| Collagen | 3 | 2000 | 636 | 0.060 |
Why?
|
| Pericardium | 2 | 2004 | 97 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 2017 | 334 | 0.060 |
Why?
|
| Retreatment | 1 | 2004 | 59 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2001 | 317 | 0.060 |
Why?
|
| Observer Variation | 2 | 2021 | 330 | 0.060 |
Why?
|
| Body Surface Potential Mapping | 1 | 2003 | 10 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2019 | 2007 | 0.060 |
Why?
|
| Pain, Intractable | 1 | 2003 | 28 | 0.060 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 2 | 2001 | 45 | 0.050 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 2001 | 52 | 0.050 |
Why?
|
| Cardiomegaly | 1 | 2004 | 213 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 87 | 0.050 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2003 | 61 | 0.050 |
Why?
|
| Constriction, Pathologic | 4 | 1998 | 236 | 0.050 |
Why?
|
| Proline | 1 | 1982 | 52 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2017 | 2358 | 0.050 |
Why?
|
| Research Design | 1 | 2007 | 729 | 0.050 |
Why?
|
| Clinical Competence | 2 | 2021 | 657 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2002 | 511 | 0.050 |
Why?
|
| South Carolina | 3 | 2013 | 2752 | 0.050 |
Why?
|
| Recombinant Proteins | 5 | 2012 | 742 | 0.050 |
Why?
|
| Receptors, Vitronectin | 1 | 2001 | 11 | 0.050 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2001 | 18 | 0.050 |
Why?
|
| Tanzania | 1 | 2021 | 35 | 0.050 |
Why?
|
| Fibrinolytic Agents | 2 | 1997 | 377 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2003 | 167 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 2 | 2002 | 69 | 0.050 |
Why?
|
| Macrophages | 2 | 2001 | 647 | 0.050 |
Why?
|
| Microspheres | 2 | 2000 | 59 | 0.050 |
Why?
|
| Incidence | 3 | 2012 | 1603 | 0.050 |
Why?
|
| Registries | 2 | 2020 | 733 | 0.040 |
Why?
|
| Biomarkers | 2 | 2019 | 1593 | 0.040 |
Why?
|
| Decision Trees | 1 | 2000 | 74 | 0.040 |
Why?
|
| Latvia | 1 | 2019 | 1 | 0.040 |
Why?
|
| Slovakia | 1 | 2019 | 4 | 0.040 |
Why?
|
| Italy | 1 | 2019 | 36 | 0.040 |
Why?
|
| Adenoviruses, Human | 1 | 1999 | 12 | 0.040 |
Why?
|
| Netherlands | 1 | 2019 | 68 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2004 | 529 | 0.040 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2000 | 99 | 0.040 |
Why?
|
| Lymphangiogenesis | 1 | 2019 | 10 | 0.040 |
Why?
|
| Vascular Patency | 2 | 2005 | 122 | 0.040 |
Why?
|
| Tretinoin | 1 | 2000 | 92 | 0.040 |
Why?
|
| Death | 1 | 2019 | 38 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 152 | 0.040 |
Why?
|
| Fibrinopeptide A | 1 | 1999 | 4 | 0.040 |
Why?
|
| Carotid Arteries | 1 | 1999 | 110 | 0.040 |
Why?
|
| Learning | 1 | 2021 | 186 | 0.040 |
Why?
|
| Prothrombin | 1 | 1999 | 12 | 0.040 |
Why?
|
| Antithrombin III | 1 | 1999 | 23 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 1999 | 92 | 0.040 |
Why?
|
| Cardiac Output | 4 | 1985 | 133 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 652 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 186 | 0.040 |
Why?
|
| Endothelium, Vascular | 2 | 1999 | 371 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2021 | 502 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2019 | 169 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 1999 | 82 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 1999 | 173 | 0.040 |
Why?
|
| Genetic Vectors | 1 | 1999 | 312 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2000 | 201 | 0.040 |
Why?
|
| Osmolar Concentration | 2 | 1991 | 134 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 1989 | 75 | 0.040 |
Why?
|
| Foam Cells | 2 | 1997 | 26 | 0.040 |
Why?
|
| Kidney | 1 | 1982 | 945 | 0.040 |
Why?
|
| Systole | 3 | 2005 | 149 | 0.040 |
Why?
|
| Heart Ventricles | 2 | 2000 | 738 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1745 | 0.040 |
Why?
|
| Radionuclide Imaging | 5 | 1997 | 166 | 0.030 |
Why?
|
| Cell Survival | 4 | 2003 | 901 | 0.030 |
Why?
|
| Sex Factors | 1 | 2000 | 1266 | 0.030 |
Why?
|
| Cell Division | 4 | 2000 | 541 | 0.030 |
Why?
|
| Erythrocytes | 1 | 1996 | 137 | 0.030 |
Why?
|
| Diuretics | 1 | 1996 | 97 | 0.030 |
Why?
|
| Cineangiography | 2 | 2000 | 15 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1038 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2004 | 2223 | 0.030 |
Why?
|
| Diastole | 2 | 1994 | 161 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1996 | 98 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 186 | 0.030 |
Why?
|
| Quinolones | 1 | 1996 | 60 | 0.030 |
Why?
|
| Postoperative Period | 3 | 2004 | 238 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 1995 | 9 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1996 | 106 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 1085 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 281 | 0.030 |
Why?
|
| Hypertension | 1 | 2004 | 1535 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 172 | 0.030 |
Why?
|
| Enalaprilat | 1 | 1994 | 4 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1330 | 0.030 |
Why?
|
| Invertebrate Hormones | 1 | 1994 | 4 | 0.030 |
Why?
|
| Algorithms | 1 | 2000 | 1196 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 1993 | 7 | 0.030 |
Why?
|
| Factor Xa Inhibitors | 1 | 1994 | 43 | 0.030 |
Why?
|
| Adenosine Diphosphate | 1 | 1993 | 66 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 1993 | 127 | 0.030 |
Why?
|
| Length of Stay | 2 | 2012 | 780 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 1993 | 34 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 42 | 0.030 |
Why?
|
| Epinephrine | 1 | 1993 | 103 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 1993 | 20 | 0.030 |
Why?
|
| Propranolol | 3 | 1993 | 103 | 0.030 |
Why?
|
| Double-Blind Method | 4 | 2002 | 1738 | 0.030 |
Why?
|
| Infarction | 1 | 1993 | 17 | 0.030 |
Why?
|
| Serotonin | 1 | 1993 | 144 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 1997 | 334 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2001 | 1174 | 0.030 |
Why?
|
| Quinolines | 1 | 1993 | 48 | 0.030 |
Why?
|
| Acute Disease | 2 | 2006 | 658 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1993 | 189 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 765 | 0.030 |
Why?
|
| Cholesterol, Dietary | 3 | 1997 | 22 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 1992 | 86 | 0.030 |
Why?
|
| Enalapril | 2 | 1989 | 86 | 0.030 |
Why?
|
| Diatrizoate Meglumine | 1 | 1991 | 1 | 0.020 |
Why?
|
| Diatrizoate | 1 | 1991 | 2 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2011 | 46 | 0.020 |
Why?
|
| Troponin I | 1 | 2011 | 34 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 65 | 0.020 |
Why?
|
| Action Potentials | 1 | 1993 | 223 | 0.020 |
Why?
|
| Iopamidol | 1 | 1991 | 37 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2012 | 119 | 0.020 |
Why?
|
| ROC Curve | 2 | 2003 | 392 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 1989 | 202 | 0.020 |
Why?
|
| Cell Count | 2 | 1997 | 248 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2013 | 384 | 0.020 |
Why?
|
| Thrombocytopenia | 2 | 2002 | 122 | 0.020 |
Why?
|
| Peptides | 1 | 1994 | 455 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2012 | 127 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2012 | 152 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1991 | 304 | 0.020 |
Why?
|
| Cardiology | 1 | 2012 | 140 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 275 | 0.020 |
Why?
|
| Densitometry | 1 | 1989 | 15 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 1991 | 233 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1989 | 219 | 0.020 |
Why?
|
| Reference Values | 2 | 2006 | 579 | 0.020 |
Why?
|
| Actins | 2 | 2001 | 249 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 592 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2012 | 400 | 0.020 |
Why?
|
| Exanthema | 1 | 2009 | 30 | 0.020 |
Why?
|
| Exercise Test | 2 | 2003 | 242 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1988 | 153 | 0.020 |
Why?
|
| Hirudin Therapy | 2 | 1999 | 3 | 0.020 |
Why?
|
| Tunica Media | 2 | 2001 | 33 | 0.020 |
Why?
|
| Microcirculation | 2 | 2001 | 77 | 0.020 |
Why?
|
| Lymphocytes | 1 | 1988 | 228 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 1988 | 231 | 0.020 |
Why?
|
| Aspirin | 1 | 2009 | 295 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 1999 | 2550 | 0.020 |
Why?
|
| United States | 1 | 2019 | 7367 | 0.020 |
Why?
|
| Radionuclide Ventriculography | 1 | 2006 | 6 | 0.020 |
Why?
|
| Partial Pressure | 1 | 1986 | 19 | 0.020 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1986 | 20 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2006 | 26 | 0.020 |
Why?
|
| Mannitol | 2 | 1984 | 25 | 0.020 |
Why?
|
| Rest | 2 | 2003 | 78 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 245 | 0.020 |
Why?
|
| Syndrome | 1 | 2006 | 255 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 249 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2001 | 951 | 0.020 |
Why?
|
| Blood Volume | 1 | 2005 | 47 | 0.020 |
Why?
|
| Body Water | 1 | 1984 | 35 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2004 | 160 | 0.020 |
Why?
|
| Plasma | 1 | 1984 | 58 | 0.020 |
Why?
|
| Regression Analysis | 2 | 1997 | 737 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2001 | 2791 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2001 | 2673 | 0.010 |
Why?
|
| Physical Endurance | 1 | 2003 | 38 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 1997 | 1040 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2003 | 80 | 0.010 |
Why?
|
| Aortic Valve Insufficiency | 1 | 1983 | 47 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1983 | 75 | 0.010 |
Why?
|
| Vasodilation | 1 | 1982 | 85 | 0.010 |
Why?
|
| Potassium | 1 | 1982 | 168 | 0.010 |
Why?
|
| Sodium | 1 | 1982 | 161 | 0.010 |
Why?
|
| Ventricular Function | 2 | 1985 | 93 | 0.010 |
Why?
|
| Creatinine | 1 | 1982 | 243 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 2003 | 208 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2003 | 215 | 0.010 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2001 | 10 | 0.010 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2001 | 6 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 349 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2001 | 106 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2001 | 94 | 0.010 |
Why?
|
| Triazoles | 1 | 2001 | 43 | 0.010 |
Why?
|
| Triazines | 1 | 2001 | 48 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2001 | 168 | 0.010 |
Why?
|
| Assisted Circulation | 1 | 1980 | 7 | 0.010 |
Why?
|
| Chemokine CCL2 | 1 | 2001 | 101 | 0.010 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1980 | 20 | 0.010 |
Why?
|
| Laboratories, Hospital | 1 | 2000 | 4 | 0.010 |
Why?
|
| Imidazoles | 1 | 2001 | 175 | 0.010 |
Why?
|
| Desmin | 1 | 2000 | 13 | 0.010 |
Why?
|
| Neutrophils | 1 | 2001 | 204 | 0.010 |
Why?
|
| Injections | 1 | 2000 | 119 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2001 | 199 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2001 | 324 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2002 | 880 | 0.010 |
Why?
|
| Cholesterol | 1 | 2001 | 331 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 649 | 0.010 |
Why?
|
| Lisinopril | 2 | 1989 | 16 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 215 | 0.010 |
Why?
|
| Mice | 2 | 2001 | 8474 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 567 | 0.010 |
Why?
|
| Punctures | 1 | 1997 | 35 | 0.010 |
Why?
|
| Skin | 1 | 1980 | 451 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2000 | 384 | 0.010 |
Why?
|
| Air | 1 | 1996 | 22 | 0.010 |
Why?
|
| Early Ambulation | 1 | 1996 | 8 | 0.010 |
Why?
|
| Rheology | 1 | 1996 | 25 | 0.010 |
Why?
|
| Clinical Nursing Research | 1 | 1996 | 17 | 0.010 |
Why?
|
| Thymidine | 1 | 1996 | 32 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1996 | 37 | 0.010 |
Why?
|
| Aorta | 1 | 1977 | 316 | 0.010 |
Why?
|
| Pressure | 1 | 1996 | 252 | 0.010 |
Why?
|
| Arteries | 1 | 1996 | 108 | 0.010 |
Why?
|
| Swine | 1 | 1997 | 672 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 1995 | 56 | 0.010 |
Why?
|
| Hypoxia | 1 | 1976 | 169 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1976 | 258 | 0.010 |
Why?
|
| Inflammation | 1 | 2001 | 1030 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1994 | 27 | 0.010 |
Why?
|
| Arthropod Proteins | 1 | 1994 | 1 | 0.010 |
Why?
|
| Leeches | 1 | 1994 | 2 | 0.010 |
Why?
|
| Ticks | 1 | 1994 | 13 | 0.010 |
Why?
|
| Angioplasty, Balloon, Laser-Assisted | 1 | 1993 | 2 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1995 | 161 | 0.010 |
Why?
|
| Angiography | 1 | 1994 | 194 | 0.010 |
Why?
|
| Metoprolol | 1 | 1993 | 8 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1993 | 29 | 0.010 |
Why?
|
| Pyrazines | 1 | 1993 | 46 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 1994 | 146 | 0.010 |
Why?
|
| Morbidity | 1 | 1993 | 130 | 0.010 |
Why?
|
| Models, Biological | 1 | 1997 | 981 | 0.010 |
Why?
|
| Tissue Survival | 1 | 1992 | 22 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1993 | 792 | 0.010 |
Why?
|
| Logistic Models | 1 | 1995 | 1420 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 186 | 0.000 |
Why?
|
| Random Allocation | 1 | 1989 | 442 | 0.000 |
Why?
|
| Rats | 1 | 1996 | 5300 | 0.000 |
Why?
|
| Mecamylamine | 1 | 1985 | 9 | 0.000 |
Why?
|
| Autonomic Nervous System | 1 | 1985 | 31 | 0.000 |
Why?
|
| Quality of Life | 1 | 1993 | 1515 | 0.000 |
Why?
|
| Blood Circulation | 1 | 1980 | 18 | 0.000 |
Why?
|
| Shock, Septic | 1 | 1980 | 101 | 0.000 |
Why?
|
| Heart Arrest | 1 | 1980 | 113 | 0.000 |
Why?
|
| Reserpine | 1 | 1977 | 24 | 0.000 |
Why?
|
| Papaverine | 1 | 1977 | 10 | 0.000 |
Why?
|
| Cardiac Volume | 1 | 1977 | 21 | 0.000 |
Why?
|
| Norepinephrine | 1 | 1976 | 276 | 0.000 |
Why?
|